Get started
TIGER GLOBAL OBESITY TREATMENT TOP2 PLUSTIGER GLOBAL OBESITY TREATMENT TOP2 PLUSTIGER GLOBAL OBESITY TREATMENT TOP2 PLUS

TIGER GLOBAL OBESITY TREATMENT TOP2 PLUS

No trades
See on Supercharts
Overview Analysis
Holdings
Discussions Technicals Seasonals

TIGER GLOBAL OBESITY TREATMENT TOP2 PLUS holdings


As of April 9, 2025
Symbol
Weight %
Shares
Shares Chg %
1M
Market value
Market value Chg %
1M
L
LLYEli Lilly and Company
25.98%
‪‪20.83 K‬‬
−29.97%
‪‪23.30 B‬‬KRW
−35.02%
N
NVONovo Nordisk A/S Sponsored ADR Class B
23.25%
‪‪215.87 K‬‬
−4.35%
‪‪20.85 B‬‬KRW
−19.44%
A
ABBVAbbVie, Inc.
10.22%
‪‪34.34 K‬‬
—
‪‪9.16 B‬‬KRW
—
R
RORoche Holding Ltd
7.57%
‪‪15.55 K‬‬
−38.77%
‪‪6.79 B‬‬KRW
−50.04%
N
NVSNovartis AG Sponsored ADR
6.71%
‪‪39.08 K‬‬
−40.83%
‪‪6.02 B‬‬KRW
−45.63%
A
AZNAstraZeneca PLC Sponsored ADR
6.68%
‪‪60.49 K‬‬
−42.59%
‪‪5.99 B‬‬KRW
−48.48%
M
MRKMerck & Co., Inc.
6.60%
‪‪48.68 K‬‬
−41.62%
‪‪5.92 B‬‬KRW
−48.70%
A
AMGNAmgen Inc.
4.97%
‪‪10.31 K‬‬
−42.05%
‪‪4.45 B‬‬KRW
−47.35%
P
PFEPfizer Inc.
4.09%
‪‪109.87 K‬‬
−41.75%
‪‪3.67 B‬‬KRW
−49.76%
4
4519Chugai Pharmaceutical Co., Ltd.
2.55%
‪‪35.08 K‬‬
−37.22%
‪‪2.29 B‬‬KRW
−38.18%
Get deeper insights with ETF data
Explore detailed ETF holdings data, including weight, shares, and market value.